Christopher Brooke - Aytu BioScience Chief Officer

Aytu BioScience Management Efficiency

The company has return on total asset (ROA) of (0.0106) % which means that it has lost $0.0106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4724) %, meaning that it created substantial loss on money invested by shareholders. Aytu BioScience's management efficiency ratios could be used to measure how well Aytu BioScience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.46 in 2024. Return On Capital Employed is likely to drop to -1.07 in 2024. At this time, Aytu BioScience's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 124 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 4.3 M in 2024.

Similar Executives

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado. Aytu Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 164 people. Aytu BioScience (AYTU) is traded on NASDAQ Exchange in USA. It is located in Denver Corporate Center III, Denver, CO, United States, 80237 and employs 102 people. Aytu BioScience is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Aytu BioScience Leadership Team

Aytu Stock Performance Indicators

Additional Tools for Aytu Stock Analysis